论文部分内容阅读
在支气管哮喘患者气道高反应(BHR)中,血小板激活因子(PAF)的参与已引起争论。为了确定是否涉及人类的BHR,作者采用口服有特效活性的PAF受体拮抗剂Y-24180来研究对哮喘患者乙酰甲胆碱诱发BHR的影响。
The involvement of platelet activating factor (PAF) has been debated in the airway hyperresponsiveness (BHR) patients with bronchial asthma. In order to determine whether human BHR is involved, the authors investigated the effect of methacholine-induced BHR on patients with asthma by oral administration of the potent and potent PAF receptor antagonist Y-24180.